Global Celecoxib API Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Celecoxib API Market Research Report 2024
Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility. The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.
According to Mr Accuracy reports’s new survey, global Celecoxib API market is projected to reach US$ 82 million in 2034, increasing from US$ 56 million in 2022, with the CAGR of 4.9% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Celecoxib API market research.
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Celecoxib API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Pharmaceutical
Laboratory
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Celecoxib API report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Celecoxib API market is projected to reach US$ 82 million in 2034, increasing from US$ 56 million in 2022, with the CAGR of 4.9% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Celecoxib API market research.
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Celecoxib API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Segment by Application
Pharmaceutical
Laboratory
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Celecoxib API report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices